Optimizing CAR-NK Cell Transduction and Expansion: Leveraging Cytokine Modulation for Enhanced Performance
- PMID: 39475383
- DOI: 10.1002/cpz1.70040
Optimizing CAR-NK Cell Transduction and Expansion: Leveraging Cytokine Modulation for Enhanced Performance
Abstract
Cellular immunotherapy has emerged as one of the most potent approaches to treating cancer patients. Adoptive transfer of chimeric antigen receptor (CAR) T cells as well as the use of haploidentical natural killer (NK) cells can induce remission in patients with lymphoma and leukemia. Although the use of CAR T cells has been established, this approach is currently limited for wider use by the risk of severe adverse events, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Moreover, the risk of triggering graft vs host reactions in settings of allogeneic T cell infusion limits the use to autologous CAR T cells if advanced CRISPR engineering is not applied. In contrast, NK cell-based cancer immunotherapy has emerged as a safe approach even in allogeneic settings. However, efficient transduction of primary blood NK cells with vesicular stomatitis virus G glycoprotein (VSV-G) pseudotyped lentivirus commonly used for T cell modification remains challenging. This article presents a detailed method that significantly enhances the transduction efficiency of NK cells by utilizing a short-term culture in cytokine-supplemented medium. It also encompasses the preparation of high-titer and high-quality lentiviral particles for optimal NK cell transduction. Overall, this protocol details the step-by-step culture of NK cells in cytokine-supplemented medium, their transduction with VSV-G lentiviral vectors, and subsequent expansion for functional assays. © 2024 Wiley Periodicals LLC. Basic Protocol 1: Isolation of NK cells from human peripheral blood mononuclear cells (PBMCs) Basic Protocol 2: NK cell expansion and transduction with lentivirus for generating CAR-NK cells Support Protocol 1: Plasmid amplification Support Protocol 2: Lentivirus preparation Support Protocol 3: Lentivirus titration.
Keywords: CAR‐NK; IL‐12; cytokines; lentiviral production; lentiviral transduction.
© 2024 Wiley Periodicals LLC.
References
Literature Cited
-
- Carlsten, M., & Childs, R. W. (2015). Genetic manipulation of NK cells for cancer immunotherapy: Techniques and clinical implications. Frontiers in Immunology, 6, 266. https://doi.org/10.3389/fimmu.2015.00266
-
- Colamartino, A. B. L., Lemieux, W., Bifsha, P., Nicoletti, S., Chakravarti, N., Sanz, J., Roméro, H., Selleri, S., Béland, K., Guiot, M., Tremblay‐Laganière, C., Dicaire, R., Barreiro, L., Lee, D. A., Verhoeyen, E., & Haddad, E. (2019). Efficient and robust NK‐cell transduction with baboon envelope pseudotyped lentivector. Frontiers in Immunology, 10, 2873. https://doi.org/10.3389/fimmu.2019.02873
-
- Depil, S., Duchateau, P., Grupp, S. A., Mufti, G., & Poirot, L. (2020). ‘Off‐the‐shelf’ allogeneic CAR T cells: Development and challenges. Nature Reviews Drug Discovery, 19(3), 185–199. https://doi.org/10.1038/s41573‐019‐0051‐2
-
- Gaggero, S., Bruschi, M., Petretto, A., Parodi, M., Zotto, G. D., Lavarello, C., Prato, C., Santucci, L., Barbuto, A., Bottino, C., Candiano, G., Moretta, A., Vitale, M., Moretta, L., & Cantoni, C. (2018). Nidogen‐1 is a novel extracellular ligand for the NKp44 activating receptor. OncoImmunology, 7(9), e1470730. https://doi.org/10.1080/2162402X.2018.1470730
-
- Hargrove, P., Kim, Y.‐S., Wielgosz, M., & Nienhuis, A. W. (2016). 530. Lentiviral vector particles pseudotyped with wild‐type baboon endogenous retrovirus (BAEV) glycoprotein outperform VSV‐G particles in transducing human CD34+ cells isolated from cytokine‐mobilized peripheral blood or bone marrow. Molecular Therapy, 24, S212. https://doi.org/10.1016/S1525‐0016(16)33339‐1
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
